Plant cell culture is expensive and technically demanding. However, new food-grade facilities operating outside biopharma cost structures could unlock unit economics that broaden its application well beyond pharmaceuticals — spanning a wide range of food and nutraceutical ingredients over the next decade. This is the prediction of new entrant Rheaplant, which recently secured fresh funding.
